Melanoma News and Research

Latest Melanoma News and Research

New ddPCR technology helps detect, quantify TERT promoter mutations linked to many cancer types

A recent study published online in the Journal of Molecular Diagnostics demonstrated that Droplet Digital PCR technology can be used to detect mutations in a region of our DNA that is linked to many cancer types, paving the way for the development of new cancer diagnostics and therapies.

31 Oct 2018

New City of Hope CAR T cell trial focuses on HER2-positive breast cancer patients with brain metastases

Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge.

30 Oct 2018

Study highlights accuracy of DecisionDx-Melanoma prognostic test in patients with Stage II-IIIA melanoma

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the presentation of data highlighting how the accuracy of the DecisionDx-Melanoma gene expression profile (GEP) test in patients with Stage II and IIIA melanoma can improve adjuvant clinical trial design at the 2018 Society for Melanoma Research International Congress held in Manchester, England from October 24-27.

30 Oct 2018

Study reveals how Seneca Valley Virus interacts with tumor receptors

Seneca Valley Virus sounds like the last bug you’d want to catch, but it could be the next breakthrough cancer therapy.

30 Oct 2018

Insights into tumor initiation pave way for new skin cancer treatments

Researchers from VIB and KU Leuven uncovered a key vulnerability of melanoma. While studying the role of the melanoma-specific long non-coding RNA SAMMSON in tumor initiation, the researchers found that it boosts protein synthesis in different cellular compartments. Normal cells are alerted by modification in protein synthesis and react to this threat, but only if this process is altered in one compartment at the time.

29 Oct 2018

UC Riverside evolutionary biologist reveals why tall people are more prone to cancer

For most cancers, risk increases dramatically with age. But what about the effect of having more cells in the body? Might taller people be more prone to cancer because they have more cells?

26 Oct 2018

Samara scholars assessed a new way of skin cancer early diagnostics

A team of scholars of Samara National Research University and Samara State Medical University as well as clinic specialists of Samara Regional Oncology Centre tested a new way of skin cancer early diagnostics with the help of original complex of three devices.

25 Oct 2018

Head and neck cancer survivors more likely to commit suicide

Despite improved survival rates among cancer patients, the risk of death by suicide remains high, especially among those treated for head and neck cancers.

25 Oct 2018

Researchers identify genes responsible for sun sensitivity and skin cancer vulnerability

Research carried out at the Health Sciences department of the Universitat Jaume I of Castellón, Spain, has identified the genes responsible for sun sensitivity and skin cancer vulnerability.

25 Oct 2018

Study suggests new strategy to kill melanoma cells

Think of the protein BH3 like a finger that turns off a cancer cell survival switch. The problem is that most cancer cells have found ways to remove this "finger" - commonly, by breaking the action of a gene called p53 that puts the BH3 finger in motion. Now think of Bcl-2 as the switch itself.

24 Oct 2018

Tall people more likely to get cancers, finds study

A new study suggests that tall people are more likely to get cancers because they have more number of cells that can undergo dangerous mutations.

24 Oct 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.

22 Oct 2018

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Study: Some countries take more time for reimbursement decisions on new cancer drugs

Some European countries take more than twice as long as others to reach health technology assessment decisions to reimburse new cancer drugs following their approval by the European Medicines Agency.

19 Oct 2018

New findings reveal potential cellular players in tumor microenvironment

New findings presented today by CytoReason reveals possible new cellular players in the tumor microenvironment that could impact the treatment process for the most in-need patients - those who have already failed to respond to ipilimumab (anti-CTLA4) immunotherapy.

16 Oct 2018

Melanoma News and Research

Latest Melanoma News and Research

New ddPCR technology helps detect, quantify TERT promoter mutations linked to many cancer types

New City of Hope CAR T cell trial focuses on HER2-positive breast cancer patients with brain metastases

Study highlights accuracy of DecisionDx-Melanoma prognostic test in patients with Stage II-IIIA melanoma

Study reveals how Seneca Valley Virus interacts with tumor receptors

Insights into tumor initiation pave way for new skin cancer treatments

UC Riverside evolutionary biologist reveals why tall people are more prone to cancer

Samara scholars assessed a new way of skin cancer early diagnostics

Head and neck cancer survivors more likely to commit suicide

Researchers identify genes responsible for sun sensitivity and skin cancer vulnerability

Study suggests new strategy to kill melanoma cells

Tall people more likely to get cancers, finds study

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Study: Targeting specific genomic mutation in breast cancer improves survival

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Study: Some countries take more time for reimbursement decisions on new cancer drugs

New findings reveal potential cellular players in tumor microenvironment

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Melanoma News and Research

Latest Melanoma News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in